Fig. 1

Comprehensive study design for assessing analytical performance of multiple pan-cancer targeted sequencing technologies. a Four samples were tested on 8 pan-cancer panels with at least 3 different test laboratories for each panel. b Basic information of 8 pan-cancer panels is listed in the embedded table (see Additional file 1: Table S1 for detailed information). *All participating panels are for research use only. ^†QGN’s UMI-aware variant caller is able to call variants with VAF as low as 0.5%. c Each sample had 4 library replicates at each test laboratory. After sequencing, panel-specific variant calling was performed by each panel vendor. d Variant calling results were submitted for performance analysis including sensitivity, false positive call rate, and reproducibility